KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Recursion Pharmaceuticals (RXRX) Gross Margin (2021 - 2025)

Historic Gross Margin for Recursion Pharmaceuticals (RXRX) over the last 5 years, with Q3 2025 value amounting to 183.81%.

  • Recursion Pharmaceuticals' Gross Margin fell 2375000.0% to 183.81% in Q3 2025 from the same period last year, while for Sep 2025 it was 59.01%, marking a year-over-year decrease of 940800.0%. This contributed to the annual value of 23.12% for FY2024, which is 186600.0% up from last year.
  • As of Q3 2025, Recursion Pharmaceuticals' Gross Margin stood at 183.81%, which was down 2375000.0% from 4.88% recorded in Q2 2025.
  • In the past 5 years, Recursion Pharmaceuticals' Gross Margin ranged from a high of 100.0% in Q1 2021 and a low of 183.81% during Q3 2025
  • Its 5-year average for Gross Margin is 1.0%, with a median of 9.27% in 2023.
  • In the last 5 years, Recursion Pharmaceuticals' Gross Margin soared by 1002300bps in 2023 and then crashed by -2375000bps in 2025.
  • Over the past 5 years, Recursion Pharmaceuticals' Gross Margin (Quarter) stood at 100.0% in 2021, then tumbled by -79bps to 20.74% in 2022, then plummeted by -55bps to 9.27% in 2023, then plummeted by -2056bps to 181.43% in 2024, then fell by -1bps to 183.81% in 2025.
  • Its Gross Margin was 183.81% in Q3 2025, compared to 4.88% in Q2 2025 and 48.04% in Q1 2025.